Œ¤‹†‚ɂ‚¢‚Ä
˜aŒ¤‹†˜_•¶

2012”N“x˜aŒ¤‹†˜_•¶

2014.11.11
yŠO•”ˆÏ‘õŒ¤‹†z

1. Ò‘‘¹‚Ì•a‘ԉ𖾂Ǝ¡—ÁEƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“–@ŠJ”­‚ÉŠÖ‚·‚錤‹†

‘啪‘åŠwˆãŠw•”@”]_ŒoŠO‰È‹³Žº

@@@@@@ “à“cW@“¡–Ø–«@

2. Cytotoxic effects of temozolomide in neuroblastomas and the sensitizing effects of levetiracetam

@@@ ‹{è‘åŠwˆãŠw•”@—Տ°_Œo‰ÈŠwuÀ@”]_ŒoŠO‰ÈŠw•ª–ì

@@@@@@ Kiyotaka Yokogami,Shinji Yamashita,Kouji Yamasaki,Ai Yamada,Hiroshi Moritake,Hiroyuki Nunoi,Hideo Takeshima

3.S•s‘SE“®–¬d‰»ŠÖ˜AŽ¾Š³‚ƍœ‘ãŽÓŽ¾Š³‚ÌŠÖ˜A«‚ɂ‚¢‚Ä‚Ì’²¸Œ¤‹†

@@ @ ‹{è‘åŠwˆãŠw•”@“à‰ÈŠwuÀ@zŠÂ‘̉t§ŒäŠw•ª–ì

@@@@@@@’ß“c•q”Ž

4.Evaluating the role of serum 1,5-anhydroglucitol concentrations as an indicator of hyperglycemic changes in diabetic and nondiabetic surgical patients

@@@ ‹{è‘åŠwˆãŠw•”@–ƒŒ¶‘ÌŠÇ—Šw

@@@@@@@Ryuji Tamura,MDEIsao Tsuneyoshi,MD,PhD

5.ƒOƒŒƒŠƒ“‚̍œŠi‹ØˆÏk‚ɑ΂·‚鎡—ÃŒø‰Ê

‹{è‘åŠwˆãŠw•”@“à‰ÈŠwuÀ_ŒoŒÄ‹z“à•ª”å‘ãŽÓŠw•ª–ì

@@@@@@@’†—¢‰ëŒõ

6.ƒRƒ“ƒsƒ…[ƒ^‰»ŒP—û‘•’u‚̗Տ°‰ž—pŠg‘å‚ɂ‚¢‚Ä ]Œ’‘¤—§‹rdŽ‹•às‚ÆŠ³‘¤‰ÁddŽ‹•às‚Æ‚ðñ‰Ád‚Æ‚ÌŠÖ˜A‚ðŒŸ“¢]

@@@ Ž­Ž™“‡‘åŠw‘åŠw‰@@ˆãŽ•Šw‘‡Œ¤‹†‰È@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆãŠw

@@@@@@@ì•½˜a”ü@‰º“°‰’Œb

y“à•”Œ¤‹†z

1.ƒgƒ‰ƒ}ƒh[ƒ‹‰–Ž_‰–/ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“”z‡ù‚Ì—L—p«‚Æ–â‘è“_‚ɂ‚¢‚Ä

@ ˜a‰ï‹L”O•a‰@ –ƒŒ‰ÈƒyƒCƒ“ƒNƒŠƒjƒbƒN

@ @@@@ @—§ŽR^Œá

2.‰Á‘¬“xƒZƒ“ƒT[‚ð—p‚¢‚½‰^“®ŠÖ˜A”]Ž¥}‘ª’è

˜a‰ï‹L”O•a‰@ —Տ°ŒŸ¸Žº

@@@@@@ @”ª–ؘaL@¼ú±’Žj@ûü‹´‹Ms@–ì’nŽµŒb@‘ˆî“c^@‰Í–슰ˆê@ŒÃ‰ê‘å‰î@’·£‘ה́@’¹Œ´—R‰À@‘“c’qŽq@’¹Œ´®Žq@’ß“c˜am

@

3.•a“‚ł̃|ƒWƒVƒ‡ƒjƒ“ƒO‚Ì“O’ê`ŠÖßSk—\–hE‰ü‘P‚æ‚èADL‚É‹y‚Ú‚·‰e‹¿`@@@@@@@@@@@

@@@@ ‰„‰ªƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@@ŠÅŒì•”

@@@@@@@ã™”ü—R‹I@ŒF–{Žé”ü@’†’J^—R”ü@–ö“c•¶”ü@b”ã‹vŒb@¡‘ºˆçŽq

4.lHŒÒŠÖß‘S’uŠ·pŒã‚ÌŒ’NŠÖ˜AQOL‚Ì—\‘ªˆöŽq‚ÉŠÖ‚·‚錟“¢

@@ @@‰„‰ªƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@@ƒZƒ‰ƒsƒXƒgŽº

@@@@@@@ˆÉ“¡GK@“ú‚‰ëm@ŽO‰YKŽ¡

5.“–‰@ICU‚É‚¨‚¯‚éŒÄ‹z—Šw—Ö@Ž{sŽž‚Ì”xƒGƒR[‚ÌŽg—pŒoŒ±

@@@@@˜a‰ï‹L”O•a‰@@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“—Ö@•”

@@@@@@@”nê‹`s

6.ãŽˆ‹@”\ŒP—û‚ɐˆÓ‰^“®‰î•Œ^“d‹CŽhŒƒ‘•’u‚ð—p‚¢‚Ẳ^“®ŠÖ˜AŽ¥ê‚̕ω»‚ÉŠÖ‚·‚錤‹†

@ ˜a‰ï‹L”O•a‰@@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“—Ö@•”

@@@@@@@ˆäã–¢—ˆ@‘å_‘PŠ°@”ª–ؘaL@–ì’nŽµŒb@‰Í–슰ˆê@‰œŽj‰À@‹ù‹´OŠì@’ß“c˜am

‘O‚̃y[ƒW‚É–ß‚é